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Abstract
While desired for the cure of allergy, regulatory immune cell subsets and nonclassi-
cal Th2-biased inflammatory mediators in the tumour microenvironment can con-
tribute to immune suppression and escape of tumours from immunological
detection and clearance. A key aim in the cancer field is therefore to design
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1 | INTRODUCTION: INSIGHTS INTO
IMMUNE TOLERANCE IN ALLERGY AND
CANCER
The immune system strives to strike a fine balance to maintain
homoeostasis. Therefore, after elimination of pathogens an immune
regulation phase follows, facilitated by checkpoint molecules, CD4+
CD25+ FoxP3+ natural regulatory T cells (Tregs),1 regulatory subsets
of B cells (Bregs) and dendritic cells (DCs), myeloid-derived suppres-
sor cells (MDSCs) and M2 macrophages, secreting immunomodula-
tory mediators such as IL-10 and transforming growth factor-b
(TGFb).2
In allergy, the immune system overreacts to innocuous allergens,
mounting Th2 responses and B-cell class switching to IgE driven by
cytokines such as IL-4 and IL-13. Allergic responses are further
amplified by a failure to adequately launch immunomodulatory
mechanisms. Allergen immunotherapy (AIT) may re-establish toler-
ance involving Tregs, IL-10 and TGFb, and class switching to anti-
inflammatory IgG4 and IgA.3
While in incipient cancer innate and adaptive immune responses
may clear some tumour cells,4 cancer-initiating cells (CiC) soon
instruct infiltrating immune effector cells to adapt regulatory pheno-
types.5 Such active immune suppression functions are accompanied
by tumour-supported accumulation of Tregs, B cells, DCs and M2
macrophages in its microenvironment, which may contribute
immunoregulatory mediators such as IL-10 or VEGF, and B cells may
express alternative Th2-biased IgG4 and IgA. Tregs have a metabolic
advantage via FoxP3 expression in low-glucose, lactate-rich tumour
environments.6 Cancer cells themselves are a prominent source of
IL-10 providing “metastatic competence”.7 Hence, while immune
infiltrates are abundant in many solid tumours (Figure 1), the tumour
microenvironment may be instrumental in maintaining suppression
and preventing immune clearance. Checkpoint inhibitor antibodies in
clinical oncology act by directly targeting T-cell tolerance mecha-
nisms with the aim of overcoming tumour-associated T-cell sup-
pression. We here extract common features in the functions of
immune modulation in allergy and cancer within the scope of
AllergoOncology.
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2 | THERAPEUTIC INTERVENTIONS TO
CONTROL IMMUNE TOLERANCE:
TRANSLATIONAL INSIGHTS IN ALLERGY
AND CANCER
2.1 | Tolerance induction with allergen
immunotherapy
As part of tolerance induction, AIT has been correlated with
enhanced regulatory T- and B-cell responses,3,8 and regulatory DCs,9
all potential sources of the immunomodulatory cytokine IL-10. A
classical hallmark of AIT is the induction of allergen-specific IgG1
and anti-inflammatory IgG4. Allergen-specific IgGs may (i) act as
blocking antibodies, trapping allergens before they can cross-link
allergen-specific IgE; (ii) interact with inhibitory IgG receptor FccRIIb
and downregulate IgE-mediated signalling10; or (iii) promote differen-
tiation of tolerogenic M2b macrophages.11 While investigation into
immune tolerance in allergy provided some insights, it is unclear
which of these mechanisms may drive tolerance or which specific
biomarkers could be used to predict clinical response to AIT.12
2.2 | The opposite side of the coin: clues into
breaking tolerance in cancer
Tumour cells and tumour-infiltrating immune cells can help to shape a
strong tolerogenic microenvironment that promotes tumour growth and
allows metastatic spread. The question of how to break tumour toler-
ance has recently become more pertinent, catalysed by the clinical effi-
cacy of checkpoint inhibitors in some tumour types, including melanoma.
Two checkpoint molecules, the cytotoxic T-lymphocyte-asso-
ciated protein 4 (CTLA-4) and the programmed cell death protein 1
(PD-1), play key roles in restricting T-cell activation and inducing
immunological tolerance that contribute to immunosuppressive envi-
ronments in cancer by multiple mechanisms. They restrict recruit-
ment, activation and proliferation of cytotoxic CD8+ T cells,13 and
their effects are amplified by tumour cells expressing CTLA-414 or
PD-1 ligand (PD-1L).15 These findings opened new avenues for inter-
vention by so-called checkpoint inhibitors.
The anti-CTLA-4 monoclonal ipilimumab was the first clinically
applied antibody that conferred tangible improvements in the treat-
ment of metastatic melanoma,16 with long-term survivors after 3 and
5 years.17 The anti-PD-1 inhibitor antibodies, nivolumab and pem-
brolizumab, also approved for the treatment of malignant melanoma,
also demonstrated significant progression-free and overall survival ben-
efits for patients with advanced melanoma. Toxic side-effects of
checkpoint inhibitors in human patients include severe autoimmunity,18
underlining the dangers when interfering in immune regulation. Clinical
trials in other malignant diseases are performed with anti-PD-1 anti-
bodies nivolumab and pembrolizumab based on better efficacy and
less toxicities compared with ipilimumab. Nivolumab is approved for
metastatic non-small-cell lung cancer (NSCLC), renal cell carcinoma
(RCC) and classical Hodgkin lymphoma (cHL)19; pembrolizumab for
NSCLC, head and neck squamous cell carcinoma (HNSCC) and classical
Hodgkin lymphoma (cHL).20 Furthermore, anti-PD-L1 (PD-ligand1) anti-
body avelumab is applied for the treatment of NSCLC,21 and others
such as atezolizumab and durvalumab22 are under clinical investigation.
OncoImmunology (alias ImmunoOncology) explores host immune
responses to tumours for uncovering insights that can lead to novel
treatments.23 Similarly, the study of Th2-type immune responses in
cancer in the emerging field of AllergoOncology24-26 may also
uncover new approaches for future treatment interventions.
3 | CELLULAR PLAYERS IN IMMUNE
TOLERANCE IN ALLERGY AND CANCER (SEE
OVERVIEW TABLE 1)
3.1 | Dendritic cells
DCs are professional antigen-presenting cells with the unique ability
to induce differentiation of na€ıve T cells into tumour antigen–specific
or allergen-specific T helper cells or CTLs. Maturation, upregulation
of costimulatory molecules (CD40, CD80, CD86) and secretion of
F IGURE 1 Immune infiltration in a human breast carcinoma. Triple negative breast cancer residual tumour section shows infiltration of
different immune cell populations in tumour stroma: CD4+ and CD8+ T cells, CD20 B cells FoxP3+ activated lymphocytes and CD68+
macrophages (CD4 [green], CD8 [red], CD20 [yellow], FoxP3 [magenta], CD68 [cyan], nuclei [blue]). The section was stained with the OPAL-7
Solid Immunology Kit and imaged on a Vectra Quantitative Pathology Workstation. Scale bar: 20 lm
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pro-inflammatory cytokines (IL-1b, IL-12, IL-6, TNFa) are required
for successful proliferative T-cell responses following DC-mediated
antigen presentation.
However, DCs also exhibit regulatory functions. IL-10-treated DCs
derived from atopic donors suppress the allergen-driven Th2-specific
response or convert T cells into Tregs.27 In particular in the tumour
microenvironment, myeloid DCs are converted into tolerogenic pheno-
types promoting Tregs rather than T-effector cells as an escape mech-
anism from immune clearance,28 supported by TGFb and IL-10.29
Tolerogenic DCs show low expression of costimulatory molecules,
secrete low levels of IL-12 and produce IL-10. Therefore, while useful
tolerance in allergen immunotherapy, antigen presentation by tolerizing
DCs is harmful in cancer as it can prevent antitumour T-cell responses.
The immunosuppressive features of DCs may be overwritten by
inflammatory signals. IgE-mediated antigen sampling is a particularly
potent mechanism to activate primary T-cell responses,30 not induc-
ing IL-10, and dampening LPS-induced IL-12 production31; irrespec-
tively, it activates CTLs via cross-presentation and improves
antitumour responses.30 Therefore, the current literature implies that
IgE-mediated antigen presentation supports DC-based immunity
rather than leading to DC-mediated tolerance.
3.2 | Macrophages
The different functional phenotypes of macrophages depend on sig-
nals from the surrounding environment. A general classification
mirroring the Th1/Th2 paradigm of classically pro-inflammatory (M1)
and alternatively anti-inflammatory (M2) macrophages is broadly
accepted.
Pro-inflammatory M1 cells are activated by mainly IFNc, LPS and
other TLR ligands. M1 were observed in exacerbation of lung injury
and airway remodelling in allergic asthma via nitric oxide produc-
tion.32 The presence of M1 macrophages in the tumour microenvi-
ronment has been associated with extended survival of cancer
patients.
M2 macrophages comprise different activation phenotypes: M2a,
M2b and M2c. M2a are triggered by IL-4 and IL-13 and positively
correlate with the severity of airway inflammation in allergic
asthma.33 In cancer, a low M1/M2a ratio was associated with poor
prognosis in a variety of murine and human malignancies.
M2b and M2c are involved in immune regulation, tissue remod-
elling, angiogenesis and tumour progression. M2b are induced by
IgG immunoglobulin complexes and LPS and are reported in the con-
text of allergy as well as cancer.34 The inhibitory IgG receptor
FccRIIb (CD32) is a critical player for signal transduction and upregu-
lation of IL-10 and CCL1 expression, while reducing IL-12. CCL1
secretion is critical to maintain the M2b phenotype in mice and
humans.35 M2c are induced by glucocorticoids, TGFb and IL-10, and
support induction of Tregs,36 which in tumours correlates with dis-
ease progression and poor prognosis.
Immune complexes with an antitumour IgE antibody or cross-
linking of surface-bound IgE can polarize monocytes and
TABLE 1 Cellular players in immune tolerance in allergy and cancer
Section Cell type Proposed roles in allergy Proposed functions in cancer
3.1 Dendritic cells Support conversion of T cells into Tregs Depending on differentiation; Support conversion of T cells into
immunosuppressive Tregs, promoting cancer progression
3.2 Macrophages M2a macrophages support allergic diseases
M2b have immunoregulatory functions
Depending on subtype; M1 macrophages support survival
Low M1/M2 ratios associated with poor survival
M2b associated with tolerogenic tumour microenvironment
3.3 Tregs Source of IL-10, supported by IL-10
Foster IgG4 production and suppress allergies
Accumulate in cancer tissue
Correlate with disease progression
3.4 Bregs Source and recipient of IL-10
Origin of IgG4 in allergen immunotherapy
Source and recipient of IL-10 origin of IgG4 in cancer tissues,
where they correlate with disease severity and poorer outcomes
3.5 Innate lymphoid
cells (ILCs)
Source of Th2 cytokines and thus
involved in initiation of allergy
Depending on subtype; ILC2 may in a tumour provide an
immunosuppressive environment, like ILC3s which
support IL-10 secretion
3.6 Mast cells Major effector cells in allergy and
source of IL-4
Controversial; Can engender pro- or antitumoral functions,
depending on microlocalization and type of tumour
A source of TNFa; Can express PD-L1 or PD-L2 and inhibit
effector T cells.
3.7 Eosinophils Involved in chronic allergic and atopic
conditions and associated with
curative processes
Controversial; Attracted by CCL1 in tumour; Can be pro-
(Hodgkin0s lymphoma) or antitumorigenic (in solid tumours);
May sense tumour cells in innate manner and kill in concert
with Igs; May induce Tregs
3.8 Epithelial cells Contribute to site-specific tolerance induction,
mainly via DC interactions; Epithelial barrier
disruption stimulates allergen entry and epithelial
activation; Source of TSLP and IL-33,
supporting Th2 responses
Source of immunosuppressive microvesicles, with a potential
role in cancer promotion
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macrophages to upregulate CD80 and the pro-inflammatory media-
tor TNFa. TNFa can then stimulate production of the macrophage
chemoattractant protein 1 (MCP-1) by both monocytes and tumour
cells, and trigger recruitment of macrophages into tumour lesions
and restriction of tumour growth.37 This macrophage TNFa/MCP-1
signalling has been reported in IgE-mediated clearance of parasites
by macrophages and brings an additional dimension to the functions
of IgE antibodies.38
Based on these multifaceted phenotypes of macrophages, block-
ing M1 pro-inflammatory or M2 anti-inflammatory macrophages may
lead to opposite effects in cancer and allergy. Targeting macrophage
functions with tumour antigen-specific IgE antibodies or vaccines
that trigger IgE responses against cancer would require careful exam-
ination.
3.3 | Tregs
The main mechanisms underpinning Treg immune effects include
production of inhibitory cytokines (IL-10, TGFb and IL-35), effec-
tor cell cytolysis (via secretion of granzymes A and B), direct tar-
geting of DCs via the inhibitory PD-1 and CTLA-4 cell surface
checkpoint molecules and metabolic disruption of effector cells
(CD25, cAMP, adenosine, CD39 and CD73).39 FoxP3+-induced
Tregs (iTregs) are mandatory, while thymic-derived natural
(FoxP3+) nTregs are dispensable for oral tolerance. In addition,
iTreg cells rather than nTreg cells are involved in the control of
mucosal Th2 responses.40
In contrast in cancer patients, Tregs contribute to an immuno-
suppressive tumour microenvironment. Accumulation of Tregs in
tumours can occur through their recruitment via chemokines (eg,
CCL-17, CCL-22, CCL-5, CCL-28), while their expansion in situ or
conversion of conventional T cells can be promoted by high local
levels of cytokines, such as TGFb.41 Specifically, the smoke com-
pound acrolein promotes regulatory cells via the arylhydrocarbon
receptor (AhR), thereby increasing malignant growth, while decreas-
ing the risk for allergic sensitization.42 High numbers of infiltrating
Tregs are associated with poor prognosis in many cancers, including
ovarian, pancreatic, lung cancer, glioblastoma or melanoma.41 There-
fore, cancer immunotherapy targeting Tregs while breaking tumour
tolerance can also break tolerance to self,43 highlighting the fine bal-
ance between antitumour immune activation and the risk of autoim-
munity.
3.4 | B cells and Bregs
B cells play key roles in inflammation, antigen presentation and anti-
body production in the context of allergy. Their contributions in can-
cer are less well delineated.
Tumour-infiltrating B cells (TiBCs) have been detected in human
solid malignancies, including melanoma,44,45 breast, ovarian, cervical,
colorectal and non-small-cell lung cancer. As in allergy,46 TiBCs show
evidence of antigen-driven expansion and somatic hypermutation,
implying active in situ antibody affinity maturation in the cancer
tissue.45 The presence of TiBCs, and B cells in tertiary lymphoid
structures (TLSs), is associated with improved prognosis in different
cancer types. Increased survival has been observed when CD8+ cells
are also detected in the same tumours, suggesting synergies
between T and B cells and induction of adaptive immune response.
TiBCs may mediate immune responses against tumours by several
mechanisms: (i) TiBC-derived antibody activities, (ii) direct cytotoxic-
ity by B-cell-secreted mediators, (iii) immunomodulation of other
TILs and promotion of TLSs, or antigen presentation.47
B regulatory cells (Bregs) can mediate allergen tolerance by IL-
10-dependent and IL-10-independent mechanisms.48 In cancer,
Bregs may function in a similar manner to promote immune toler-
ance or potentiate Treg responses, leading to tumour progres-
sion.47,49,50 The latter is consistent with TiBCs found in close
proximity to FoxP3+ T cells in melanoma lesions and in other tumour
types.44 Specific compartments and actions of B cells may thus be
targeted to improve treatment of allergic or malignant diseases.
3.5 | Innate lymphoid cells (ILCs)
Innate lymphoid cells (ILCs) broadly mirror helper T-cell subsets, but
they do not express specific antigen receptors. Based on their lin-
eage-specific transcription factor and cytokine production, they are
classified in 3 groups.51 ILC1s phenotypically like Th1, respond to IL-
12, IL-15 and IL-18, and are defined by the production of IFNc and
expression of transcription factor T-bet. NK cells expressing eomeso-
dermin and producing cytotoxic granzymes and perforin also belong
to that group. ILC2s, which resemble Th2 cells, respond to epithe-
lium-derived cytokines, such as IL-33, IL-25, TSLP, eicosanoids and
IL-1b. The cells are defined by production of type 2 cytokines IL-4,
IL-5, IL-9 and IL-13 and by the expression of the transcription factor
GATA-3.
ILC2s are involved in the initiation of innate allergic inflammation
and in its enhancement by interacting with other immune cells. They
are stimulated by epithelial cells (through IL-33, IL-25, TSLP) or by
proximal mast cells (via IgE-mediated eicosanoid release) that induce
type 2 cytokine production from human ILC2s.51 On the other hand,
ILC2s are negatively regulated by IL-33-activated mast cells that
suppress them via Treg cell expansion or by KLRG1 (produced by
ILC2 after stimulation with IL-33 or TSLP)/E-cadherin (expressed by
keratinocytes) axes.
In cancer, IL-33 secreted by macrophages stimulates ILC2s and,
in turn, the secretion of IL-13 and IL-5, which have pro-tumoral
effects. ILC2s can also establish an immunosuppressive tumour
microenvironment by amphiregulin secretion.52
ILC3s resemble Th17 and Th22 cells. They respond to IL-1b and
IL-23 and are defined by the production of IL-17A and IL-22 and by
the expression of RORct.53 Furthermore, cells of the ILC3 subtype
secrete IL-22 upon IL-23 stimulation by macrophages and have
tumorigenic effects. On the other hand, ILC3s could induce tolerance
by increasing IL-10 and retinoic acid secretion by DCs upon stimula-
tion by microbiota and macrophages,54 or by enabling T-cell toler-
ance through the expression of MHC Class II in the absence of
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costimulatory molecules.55 Thus, among the ILC type, especially the
ILC3s could favour tumour growth and tolerance.
3.6 | Mast cells
Mast cells are major players in allergy, but also accumulate in the stro-
mal and intratumoral tissues of a diverse array of cancers. Mast cells
are chemoattracted by different factors such as stem cell factor (SCF),
vascular endothelial growth factor (VEGF), chemokines, prostaglandins,
leukotrienes, histamine and osteopontin56 in the tumour microenvi-
ronment. The controversial role of mast cells in tumorigenesis and
tumour progression could possibly depend on their micro-localization
and the type of tumour. Their contribution to human tumour growth
has mostly been assessed by relating the number of mast cells in can-
cer tissue to the stage and/or prognosis of the disease, while gener-
ally no markers for functional activity were taken into account.56,57
The net outcome of mast cell accumulation for the tumour cells may
be determined by the condition of the tumour micromilieu shaping
local pH and oxygen tension.56,58,59 Upon activation, mast cells can
release a great number of prestored and newly synthesized mast cell
mediators, which can stimulate tumour growth (see below).
Furthermore, mast cells express cell surface molecules, which
upon contact with target cells inhibit cell activation or may polarize
mast cells towards tolerance induction. Expression of PD-L1 or PD-
L2 on mast cells may contribute to inhibition of T-cell activation in
the tumour microenvironment.60 Furthermore, co-culture of human
mast cells with immature DCs stimulates their expression of PD-1
and programs DCs towards tolerogenicity supporting induction of
regulatory T cells.61 The impact of the mast cells checkpoint inhibi-
tors for tumour development requires further research.
3.7 | Eosinophils
Eosinophils were found mainly antitumorigenic in solid tumours such
as bladder, gastrointestinal, melanoma, prostate, with only some
studies showing a detrimental effect in favour of tumour growth
such as in the case of Hodgkin lymphoma.62 Mechanistically, CCL1
produced by tumour cells can attract eosinophils (via CCR3) that
may interfere with tumour growth.63 Tumour cells can stimulate
eosinophils to produce IL-18, which in turn facilitates eosinophil-can-
cer cell interactions leading to tumour cell death.64 Production and
secretion of ROS and cytotoxic mediators, typical eosinophil media-
tors, were found antitumorigenic in many cancer studies.65 Never-
theless, the growth factor APRIL could support growth of malignant
plasma cells in bone marrow in a multiple myeloma mouse model.66
More recent studies place eosinophils as first line “sensors” for the
general antitumour immune response, showing for example, that
intratumoral eosinophils are crucial for the recruitment of antitumour
CTLs in melanoma.67 On the other hand, lung eosinophils were
shown to induce Treg infiltration and consequently support lung
metastasis.68 Lastly, eosinophils are involved in curative processes
induced by checkpoint inhibitor immunotherapies (eg, ipilimumab or
pembrolizumab69).
Hence, numerous findings suggest that eosinophils can be an
immunotherapeutic effector cell either being activated by
immunotherapies such as checkpoint inhibitors, or granulocyte-
macrophage-colony-stimulating factor (GM-CSF)-based vaccines,70 or
perhaps by adoptive transfer of these cells in an appropriate set-
ting.71
3.8 | Epithelial cells
The essential contribution of the epithelial barrier to a balanced
immune response is well established. For oral antigens, the site of
antigen uptake and its particulate nature is decisive for the subse-
quent immune response.72 Antigen passage through mucus-produ-
cing goblet cells has been specifically associated with tolerance
induction.73 In allergy as well as cancer, the cell surface receptor
repertoire of epithelial cells includes the high-74 and the low-affinity
IgE Fc receptors facilitating antigen passage and directing antigen
presentation.75 The epithelium is additionally an important cytokine
source, profoundly modulating the immune response (Table S1).
In the intestinal tract, extracellular vesicles physiologically produced
from intestinal epithelial cells contribute to innate immunosup-
pression,76 which may contribute to oral tolerance—or cancer
progression.
4 | MOLECULES IN IMMUNE TOLERANCE:
FROM ALLERGY TO CANCER (SEE
OVERVIEW IN TABLE 2)
4.1 | IgG4 antibodies
IgG4 is the least abundant subclass of IgG in normal human serum,
but it may reach elevated levels following chronic exposure to anti-
gen, or during inflammation. IgG4 has unique structural characteris-
tics that are responsible for its inability to fix complement, low
affinity for activating FccRs, and relatively high affinity for the inhibi-
tory Fc receptor FccRIIb.26 IgG4 has a unique ability to undergo
Fab-arm exchange, resulting in the formation of bispecific antibodies
which are functionally monovalent, and are therefore not able to
cross-link antigens to form large immune complexes.44 For these rea-
sons, IgG4 are widely considered to be anti-inflammatory antibodies,
playing a positive and protective role in allergy and helminth infec-
tions. On the other hand, in IgG4-related diseases, such as sclerosing
pancreatitis and autoimmune pancreatitis (AIP), pathogenic roles for
IgG4 cannot be fully precluded yet. In contrast, the anti-inflamma-
tory properties of IgG4 may have a negative impact in the context
of cancer. As tumours are characterized by chronic inflammation
with prolonged exposure to tumour-associated antigens, elevated
IgG4 has been detected in extrahepatic cholangiocarcinoma, pancre-
atic cancer, melanoma45 and glioblastoma.77 Indeed, these tumour
types are characterized by Th2-biased expression of mediators
known to trigger B cells to produce IgG4. Tumour-specific IgG4 may
act as a blocking antibody competing with inflammatory antibodies
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such as IgE or IgG1 for binding to antigen, or in form of immune
complexes engage the inhibitory receptor FccRIIb and thus dampen
the inflammation. IgG4 antibodies in cancer may thus have a darker
side, as compared to their association with tolerance induction to
allergens.
4.2 | IgE and IgG repertoires in allergy and cancer
New-generation sequencing for immunoglobulin repertoire analysis78
was applied in subcutaneous AIT79 and longitudinal studies of cancer
progression.80 Also the IgG repertoire of healthy individuals con-
tained antibodies to tumour-associated carbohydrate antigens, with
a possible function immunosurveillance.81
A study of IgE sequences in the blood and nasal biopsies of eight
allergic rhinitis patients undergoing SIT79 compared the repertoires
at baseline and after 2 months and 1 year of SIT with the library of
paired allergen-specific IgE heavy- and light-chain variable region frag-
ment (scFv) sequences selected at baseline by phage display. The
allergen-specific IgE clones showed increased persistence, higher likeli-
hood of clones related to other switched isotypes, and larger clonal
families. Related IgG clones may represent the putative competitors
for allergen responsible for the acquired allergen tolerance.82,83
Studies of the immunoglobulin repertoire in cancer are rare. The
study of a multiple myeloma patient not only confirmed the mono-
clonality of the myeloma cells, previously observed in conventional
low-throughput sequencing, but also demonstrated certain pitfalls in
the massively parallel sequencing technology.80 Another study of 15
B-cell acute lymphoblastic leukaemia (B-ALL) patients tracked the
clonal diversification of the malignant cells and found that large
numbers of small subclones, present at diagnosis, re-emerged at
relapse alongside a dominant clone.84 The technology detected mini-
mal residual disease with unprecedented sensitivity and framed early
cyto-reduction, such as surgery and radiation to reduce the tumour
bulk, as an important determinant of long-term survival.
Immunoglobulin repertoire analysis by new-generation sequenc-
ing can in future provide a rich source of information relating to
immuno-biology and immuno-therapeutics in allergy as well as
cancer.
4.3 | Free light chains (FLC)
Free light chains (FLC) are produced and secreted in excess to
immunoglobulin heavy chains during synthesis of tetrameric
immunoglobulins by plasma cells and can be detected in all body flu-
ids. Significant increases in systemic and local polyclonal FLC levels
have been measured in many chronic inflammatory diseases, includ-
ing allergic diseases (such as asthma, rhinitis), chronic obstructive
pulmonary disease (COPD), multiple sclerosis, rheumatoid arthritis,
inflammatory bowel disease, diabetes and cancer.57,85 FLC can
induce inflammatory responses by mediating antigen-specific mast
TABLE 2 Molecules in immune tolerance in allergy and cancer
Section Molecule Function in allergy In cancer
4.1 IgG4 antibodies Induced in allergen immunotherapy; Function as
blocking antibodies and via FccRIIb
Overexpressed in some malignancies
Derived from intratumoral Bregs
Correlate with progression
4.2 IgE and IgG repertoires IgE: the major effector antibody in immediate-type
allergies, via high-affinity binding to FceRI; Responsible
for antigen cross-presentation to T cells; IgE clones
have increased persistence, more likely related to
other switched isotypes, larger clonal families
IgE and IgG: monoclonality in myelomas; Small
subclones re-emerged at relapse alongside
a dominant clone in B-cell leukaemia
4.3 Free light chains (FLC) Increased polyclonal FLC levels in allergies
Activate mast cells
Increased FCL: biomarker for poor prognosis in
basal-like breast cancer
4.4 Regulatory cytokines
and chemokines
IL-10 and TGF-b have pivotal role in tolerance
establishment to allergens; CCL1:CCR8 axis plays
a master role in immune regulation
IL-10 and TGF-b derived from immune and cancer
cells shape the immunosuppressive environment
in cancer and correlate with disease progression;
Controversial: the role of the CCL5:CCR5 axis;
CCL3, -4, -5 derived from intratumoral
myeloid-derived suppressor cells (MDSCs)
can recruit Tregs
4.5 Mast cell mediators
and receptors
Secreted mediators and cytokines that support
allergy and acute inflammation
Interact with IgE and other isotypes
Controversial; Can stimulate tumour growth (eg,
histamine, NGF, IL-8), neovascularization (eg,
VEGF, heparin, TGFb), and suppress effector
T cells, enhance Tregs via amphiregulin; On
the contrary, can inhibit tumour growth, cause
apoptosis (eg, via TNFa, IFNc, PAR-1/2), and
attract leucocytes (eg, IL-8, TNFa), inhibit
metastasis via chondroitin sulphate
4.6 Lipocalins (LCN) Sequester iron; LCN and iron levels decreased in
allergy; Some allergens belong to the lipocalin
family themselves
LCN and iron levels are upregulated in cancer;
form complexes with matrix-metallopeptidase 9
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cell activation86 and also reduce neutrophil apoptosis and stimulate
their release of pro-tumorigenic IL-8. The expression of FLC was
found to be a biomarker for poor prognosis in basal-like breast can-
cer.87 In a preclinical melanoma model, it was further demonstrated
that FLC-induced mast cell activation-stimulated tumorigenesis.87 As
FLC were found in the stromal tissues of a great number of human
tumours, one could speculate that overall FLC may contribute to
cancer growth and progression.
4.4 | Regulatory cytokines and chemokines
Without doubt among cytokines, IL-10 and TGFb are pivotal in the
establishment of immune tolerance, and their production by many
different cell types is desirable in allergy3 but unwanted in cancer, as
discussed above. For instance, CCL1 is a chemokine expressed by
monocytes and especially by the tolerogenic M2b macrophage sub-
population, after engagement of FcyRIIb and LPS or by IL-1b stimu-
lation.35,88 CCL1 may be potentiated by the expression of its
cognate receptor CCR8 on CCR8+ FoxP3+ Treg cells, and by the
CCL1:CCR8 axis in immune regulation.89
Growing interest has recently emerged on the role of the CCL5:
CCR5 axis (and other CCL5 receptors, CCR1 and CCR3; and CCR5
ligands, CCL3 and CCL4) in cancer progression, but also in the possi-
bility to exploit this chemokine-receptor interaction to combat can-
cer. Depending on the tumour environment, CCL5 has been
implicated in antitumour adjuvanticity but also in carcinogenesis.
Intratumoral myeloid-derived suppressor cells (MDSCs) can mediate
recruitment of Tregs through the secretion of CCL3, CCL4 and
CCL5 acting on the CCR5.90 Specifically tailored interventions on
CCR5 expressed by tumour cells or by tumour stromal cells resulted
in antitumour effects.91,92 Interestingly, CCL5 and CCR5 are involved
in immune tolerance and in the recruitment and activation of
MDSCs.93,94 This CCL5:CCR5/MDSC axis may provide yet another
important link between allergy and cancer. An example may be the
association of chronic food allergy and the development of colorec-
tal cancer via mast cell-mediated recruitment of MDSCs.95 There-
fore, while the acute allergic reactions per se via the cytokine and
chemokine systems should stimulate the immune system and elevate
tumour surveillance, any prolonged chronic inflammation supports
tumour development.
4.5 | Mast cell mediators and receptors
As discussed above, despite their pro-inflammatory functions, mast
cells can have a prominent role in the induction of immune toler-
ance. Among the prestored and newly synthesized factors, some
stimulate tumour growth (eg, histamine, nerve growth factor [NGF],
IL-8), neovascularization (eg, VEGF, heparin, TGFb), and can restrict
T-cell responses.96 On the other hand, mast cells can also secrete
mediators which are detrimental to the tumour by inducing growth
inhibition, cellular disruption and apoptosis (eg, TNFa, IFNc, activa-
tion of PAR-1/2), and by attracting inflammatory leucocytes (eg, IL-
8, TNFa), and inhibiting metastasis (eg, chondroitin sulphate). Of
note, the mast cell-derived enzymes chymase and tryptase can be
both beneficial and detrimental.
Histamine can modulate different immune cells via the histamine 2
(H2) receptor. This could have juxtaposed functions, such as enhanced
mobilization of DCs, reduction in cytolytic activity of NK cells and
modification of MDSCs.97 Interestingly, ranitidine, an H2 receptor
antagonist, was inhibited lung metastasis and breast cancer develop-
ment in mouse models.98 Mast cells can also release immunosuppres-
sive IL-10 and TGFb,97,99 tryptophan hydroxylase-1 (thp-1) and
amphiregulin.100,101 thp-1 deficiency in mast cells results in slower
tumour growth kinetics.100 The exact mechanism by which thp-1 regu-
lates immune responses is still unclear. Amphiregulin stimulates the
epidermal growth factor receptor (EGFR), enhances Treg function and
contributes to the local immunosuppression in the tumour micromi-
lieu.101 All these suggest an important role of mast cell mediators in
immunoregulation.
4.6 | Lipocalins
Many innate defence proteins are differentially regulated in allergy
and cancer, for instance lipocalin-2 (LCN2; NGAL). LCN2 is highly
expressed in the liver, bone marrow, spleen, salivary gland, the colon,
the lung and the kidney. LCN2 is upregulated in various cancer types
and has been proposed as a cancer biomarker.102-104 LCN2 binds iron
through iron-chelating compounds.105 As such, it is involved in
numerous processes including innate immunity, apoptosis and renal
development. It can also form complexes with the matrix-metallopep-
tidase 9 (MMP9, a 92-kDa gelatinase), itself being a poor prognostic
factor in several cancer types.106 Increased iron raises the cancer risk
and as a participant in iron homoeostasis also LCN2 is upregulated in
various cancers.107 Contrastingly, decreased LCN2 and serum iron
are associated with allergy.108 Some exogenous antigens have a strik-
ing structural resemblance with human LCN2,109,110 suggesting
potential interference with the iron loading of endogenous LCN2 and
affecting its immunomodulatory potency. Taken together, LCN2
could assume divergent immune roles in allergy and cancer.
5 | ANIMAL MODELS AND IMMUNE
TOLERANCE IN ALLERGY AND CANCER
The induction of allergy, often followed by re-establishment of toler-
ance, are important goals in allergic animal models, mostly
mice.111,112 A range of humanized mouse models (immunocompro-
mised mice engrafted with nonmalignant human peripheral blood
lymphocytes or mononuclear cells or hematopoietic stem cells) are
used for studies on allergies.113 Comparisons among allergy mouse
models are difficult as the responses vary widely.114 Moreover, com-
ponents of the human allergic response (mast cells, allergen-specific
IgE and eosinophils) are unnecessary for allergy induction in certain
mouse models, especially allergic asthma models. Brown Norway rats
are helpful as they develop food allergy upon high-frequency intra-
gastric dosing of allergen without adjuvant.114 However, large
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amounts of antigens are needed.111,114 Dogs spontaneously develop
allergies, but drawbacks are the high cost, limited number of strains,
and greater interanimal variation compared to rodents.111 Increas-
ingly, allergic canine patients are introduced in comparative allergy
studies.112 Swine share dog’s advantages and disadvantages plus the
limitation of long dosing times required for sensitization.111
In cancer animal models, tolerance to implanted or artificially
expressed malignant cells is needed from the onset of the experi-
ment, followed by either tumoricidal approaches or efforts to break
tumour tolerance such as by immunotherapeutic approaches.
Immunocompromised mice bearing human xenograft tumours have
been extensively used to study anticancer drugs,115 but lack an
adaptive immune response. This can be overcome using immuno-
competent mice or rats bearing syngeneic tumours, which respond
to a broad variety of immuno-stimulatory approaches such as anti-
bodies (including IgE), antibody fusion proteins and cancer vac-
cines.115-117 However, differences to the rodent immune system
limit the translation of these models to humans.115 Transgenic mice
originally developed to study allergic responses and therapeutics, for
instance those expressing specific IgE Fc receptors, may be used in
the cancer setting. Alternatively, humanized mice with human
immune cells have been employed.115,118 These mouse models can
be challenged with human tumours to evaluate immuno-stimulatory
anticancer agents.118 Hurdles of humanized mice are the suboptimal
engraftment of nonmalignant cells and their inadequate maturation
in cases where stem cells are engrafted; however, humanized mice
are promising models for both studies on allergies and malignancies
whose improvement continues.118 Dogs are an up-and-coming com-
parative model in AllergoOncology due to their high incidence of
spontaneous malignancies in an intact immune system setting, and
because they can sometimes develop allergies119; however, there are
limited canine-specific/cross-reactive reagents and epitopes charac-
terized for immunotherapy use.120 Cynomolgus monkeys are often
used to evaluate toxicity of anticancer agents due to their phyloge-
netic proximity to humans. Differences in the immune system com-
pared to humans can still be problematic, especially when examining
checkpoint inhibitors and other immuno-stimulators,121 and this
model is expensive and not practical to address antitumour activity.
6 | CONCLUSION
Insights from research in allergen immunotherapy and cancer immunol-
ogy strongly suggest that the same key immune cells are involved in
immune tolerance induction in allergy and also in cancer (Table 1; Fig-
ure 2). DCs, as well as other cells including mast cells, may not only
play pivotal roles in CTLA-4 and PD-1 mediated Treg activation in
allergy, but also can help shape a strong immunosuppressive microenvi-
ronment with detrimental effects in cancer. Notably, tumour antigen–
specific IgE could break DC-mediated tolerance and also repolarize
macrophages to a phenotype that can promote antitumour responses.
Particularly, among innate cells, M2b and ILC3 subtypes are expressed
in cancer and correlate with disease progression and poor prognosis.
Tregs and Bregs, possibly via IL-10 and other molecules (Table 2),
can also contribute to an immunosuppressive tumour microenviron-
ment and can be promoted by environmental triggers through AhR.
Mast cells and eosinophils express cell surface molecules, which upon
contact with target cells, can polarize these cells towards tolerogenic
phenotypes. Mast cells simultaneously stimulate tumour growth via
factors such as histamine or NGF, and manipulate T-cell responses in
favour of immunosuppression. IL-10 and TGFb, CCL1 and CCL5 and
their axes to CCR8 and CCR5 could support tolerance induction. The
contrasting immune effects of single molecules are illustrated by the
increased LCN2 levels in cancer, while decreased in allergy.
In contrast to their beneficial effects in AIT, the IgG4 subclass
and also FLCs may have poignant significance in cancer. In contrast
to allergy, little is known about the specificity of immunoglobulins in
cancer, but repertoire analysis by new-generation sequencing pro-
vides a future source of information. For all AllergoOncology
approaches, including those interrogating immune tolerance, emerg-
ing allergy and oncology know-how must be combined to design
optimal in vivo models.
Collectively, there are many parallels to be drawn between toler-
ance mechanisms at play in allergy and cancer, albeit with contrast-
ing implications on disease progress and patient outcomes. The
pursuit of further insights into these parallel mechanisms with juxta-
posed clinical consequences has the potential to lead to novel thera-
peutic interventions to benefit both disciplines.
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